Retatrutide (reta peptide): dosage, side effects and trial results. | Reddit

Retatrutide is a single synthetic peptide with agonist activity at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon. That is the whole of what the name describes. It carries the development code LY3437943 in the trial literature, and “reta peptide” is forum shorthand, not a separate compound or a different formulation.

It is investigational, which has a specific meaning: it is being tested in registrational trials so a sponsor can assemble an evidence package for a regulator. It is not a compound that circulated in wellness clinics and later attracted research. Every figure on this page traces to one of seven human trial reports, plus review articles that summarise them and are labelled as reviews where they are cited.

Each of the three receptors sits on a different part of metabolic regulation, and the design premise is that engaging all three does something the single-receptor and dual-receptor drugs do not. A 2024 review in European Journal of Pharmacology describes the proposed mechanism as a synergistic interaction across the three receptors producing increased insulin secretion, improved glucose homeostasis and appetite modulation.

A 2026 review in Endocrine Reviews places retatrutide in a broader class: next-generation agents that engage GLP-1 plus other gastro-entero-pancreatic hormone receptors, including GIP, glucagon, amylin and peptide YY, to affect energy uptake, storage and expenditure through combined mechanisms.

There is no approved dose, because there is no approved indication. What exists is a set of dose arms assigned inside controlled trials, under supervision, with monitoring and predefined stopping rules. The clearest published list comes from a phase 2 study in adults with type 2 diabetes: 275 participants received once-weekly placebo, dulaglutide 1.5 mg, or retatrutide at 0.5, 4, 8 or 12 mg (Diabetes, Obesity & Metabolism, 2025, human).

The obesity program used the same upper doses. The 2024 Nature Medicine report describes a 48-week phase 2 obesity study with 8 mg and 12 mg arms. The phase 2 obesity trial published in the New England Journal of Medicine in 2023 was designed specifically because the dose-response relationships for side effects, safety and efficacy in obesity were not known.

The most-quoted numbers come from the 48-week phase 2 obesity study, summarised in the 2024 Nature Medicine report: mean weight reductions of 22.8% with retatrutide 8 mg and 24.2% with 12 mg. These are group means from a randomised trial in a selected population, not a projection for any individual.

A 2025 systematic review and meta-analysis in Proceedings (Baylor University Medical Center) pooled randomised controlled trials comparing retatrutide with placebo in people with obesity, with or without diabetes, from database inception to May 2024. A 2025 systematic review in Pharmacological Reviews assessed phase 2 and phase 3 trials of emerging obesity pharmacotherapies against placebo or an approved weight-loss medication.

The diabetes program is the more advanced half of the picture. The 2023 Lancet phase 2 trial ran in the USA as a randomised, double-blind, double-dummy study with both a placebo arm and an active comparator, examining efficacy and safety across a range of doses. Its stated framing was that in current type 2 diabetes guidance, bodyweight management matters as much as hitting glycaemic targets.

In 2026 the phase 3 TRANSCEND-T2D-1 trial reported in The Lancet: a 40-week, randomised, double-blind, placebo-controlled study at 48 sites across the USA, Mexico and India, testing retatrutide as monotherapy in adults whose type 2 diabetes was not controlled by diet and exercise alone.

People asking how long retatrutide takes to work are usually asking about individual onset, which no published trial reports. What the trials report is a fixed set of measurement points, and each headline figure belongs to one of them. Reading a 48-week number as a 12-week expectation is the most common way these results get misquoted.

Safety is the endpoint the registrational program is built around, and it is the part of the record that is still being written. The phase 2 obesity trial in the New England Journal of Medicine was run precisely because the dose-response relationship for side effects and safety in obesity was not known. The phase 3 trials name safety alongside efficacy in their stated objectives.

Consumer pages routinely publish confident side-effect lists with percentages attached. This page does not restate numbers it cannot trace to one of the listed trials. What follows is what the published record shows was measured, and what it does not yet answer.

Lean mass is a live question for the whole incretin class, not for retatrutide alone. A 2024 narrative review in Diabetes Care examines the degree to which incretin-based weight-loss medications, naming retatrutide among them, cause loss of lean mass, and argues for resistance exercise to preserve muscle during treatment.

It is also why the body-composition substudy exists. Measuring total body fat mass against placebo and an active comparator at week 36, rather than reading the scale, is how a trial separates fat loss from overall weight loss.

There is no price, because there is no product. A drug in registrational trials has no marketing authorisation, no national drug code, no pharmacy dispensing channel and no insurance coverage. Pricing for this class is set after approval, by the sponsor, and nothing in the published trial record establishes a figure.

Numbers that appear in search results for this query are vendor listings for material sold as a research chemical. A price on a website establishes what someone will charge. It establishes nothing about identity, purity, sterility or dose accuracy.

In registrational phase 3 trials, which is the stage at which a sponsor generates the evidence a regulator reviews. Two published programs mark the position. The TRANSCEND-T2D-1 phase 3 trial in type 2 diabetes reported in 2026. The TRIUMPH program, described in a 2026 Diabetes, Obesity & Metabolism design paper, is four phase 3 multicenter randomised double-blind studies using a basket design to evaluate obesity together with two related conditions, obstructive sleep apnea and knee osteoarthritis.

A basket design of that shape is a signal of intent: the sponsor is pursuing obesity and its complications concurrently rather than sequentially. It is not a signal about the outcome. Registrational trials exist because a phase 2 result can fail to replicate.

The mechanism here is worth stating precisely, because it is usually stated wrong. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded medication qualifies for its regulatory exemptions only if the bulk substance has a USP monograph, is a component of an approved drug, or appears on the FDA 503A Bulks List. An investigational molecule still in registrational trials is none of those.

The practical effect is that compounding it falls outside those exemptions, which makes the resulting product an unapproved new drug and exposes the pharmacy to FDA enforcement. That is an enforcement posture, not a criminal prohibition by name, and it is why no licensed pharmacy network supplies it.

The comparison people want is a head-to-head. It does not exist. What exists is separate trial programs at different stages, summarised in review articles. A 2025 review in Expert Opinion on Investigational Drugs reports liraglutide 3.0 mg daily at 6 to 8% weight loss, semaglutide 2.4 mg once weekly at about 12 to 15%, and the dual GIP/GLP-1 agonist tirzepatide once weekly at about 20% in people with obesity without diabetes. A 2025 review in the International Journal of Obesity gives semaglutide 2.4 mg once weekly, an agent approved for obesity treatment in 2021, at 15 to 17% mean weight loss.

Those two review figures for the same drug differ, which is the honest state of the literature and a reason to treat any single number as a range rather than a fact.

Nobody selling it can demonstrate that it is, and no trial studied it. Research chemical vendors list the name and ship a vial labelled for research use only, not for human consumption. That label is what allows the sale, and it is also an explicit statement that the seller is not offering a medicine.

The trial results on this page were produced with a defined product of known identity, concentration and sterility, given under monitoring. Nothing about a 22.8% figure transfers to an unverified vial.

If the underlying goal is metabolic and weight management support, there are therapies a licensed clinician can prescribe today and a licensed US pharmacy can prepare today. Semaglutide and tirzepatide both have approved products behind them and an established prescribing route, and a clinician decides whether either is appropriate for your history.

Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. The online visit is free, and you pay only if a clinician prescribes.